血栓切除术后无复流现象的灌注影像定义比较——哪种灌注影像定义最佳?
本研究在两项国际随机对照试验(EXTEND-IA TNK第1和第2部分)及一项多中心前瞻性观察研究中,对131例血管内治疗成功再通(eTICI2c-3)且完成24小时灌注影像的患者,外部验证了4种已发表的无复流影像定义。结果显示不同定义间无复流患病率差异显著(0.8%-22.1%,p<0.001),定义间一致性差(kappa 5/6比较<0.212)。以>15% CBV或CBF不对称定义无复流是唯一改善BIC模型拟合(ΔBIC=-8.105)且与90天功能预后相关的定义。
要点
- 不同无复流影像定义间患病率差异显著(0.8%-22.1%,p<0.001)。
- 定义间一致性差(kappa 5/6比较<0.212)。
- >15% CBV或CBF不对称定义最佳区分90天功能预后。
核心结论
- 现有无复流影像定义在患病率和治疗后灌注影像特征上存在显著差异,可能解释文献中报道的无复流患病率差异。
- >15% CBV或CBF不对称定义对90天功能预后区分最佳,包括eTICI3再通患者。
研究设计与样本
- 对4种已发表无复流定义进行外部验证,纳入EXTEND-IA TNK第1和第2部分两项国际随机对照试验及一项多中心前瞻性观察研究中eTICI2c-3再通且完成24小时灌注影像的患者,共131例分析。
主要发现
- 131例患者中,不同定义间无复流患病率显著不同(0.8%-22.1%,p<0.001)。
- 定义间一致性差(kappa 5/6比较<0.212)。
- 至少符合1种定义的无复流患者中,不同定义间病灶内CBF(p=0.006)、CBV(p<0.001)和MTT(p=0.005)的侧间差存在显著差异。
- 3种定义的无复流与90天mRS≥3相关。
- >15% CBV或CBF不对称定义是唯一改善BIC模型拟合(ΔBIC=-8.105)并显示无复流与eTICI3再通患者临床预后相关的定义。
关键数值与推荐
- 无复流患病率范围0.8%-22.1%(p<0.001)。
- 定义间kappa 5/6比较<0.212。
- >15% CBV或CBF不对称定义ΔBIC=-8.105。
临床怎么用
- 作者认为>15% CBV或CBF不对称定义对90天功能预后区分最佳,包括eTICI3再通患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The no-reflow phenomenon is a potential contributor to poor outcome despite successful thrombectomy. There are multiple proposed imaging-based definitions of no-reflow leading to wide variations in reported prevalence. We investigated the agreement between existing imaging definitions and compared the characteristics and outcomes of patients identified as having no-reflow. METHODS: We performed an external validation of 4 existing published definitions of no-reflow in thrombectomy patients with extended Thrombolysis in Cerebral Infarction scale 2c to 3 (eTICI2c-3) angiographic reperfusion who underwent 24-hour perfusion imaging from 2 international randomized controlled trials (EXTEND-IA TNK part-1 and 2) and a multicenter prospective observational study. Receiver-operating-characteristic and Bayesian-information-criterion (BIC) analyses were performed with the outcome variable being dependent-or-dead at 90-days (modified Rankin Score [mRS] ≥3). RESULTS: Of 131 patients analyzed, the prevalence of no-reflow significantly varied between definitions (0.8-22.1%; p < 0.001). There was poor agreement between definitions (kappa 5/6 comparisons <0.212). Among patients with no-reflow according to at least 1 definition, there were significant differences between definitions in the intralesional interside differences in cerebral blood flow (CBF) (p = 0.006), cerebral blood volume (CBV) (p < 0.001), and mean-transit-time (MTT) (p = 0.005). No-reflow defined by 3 definitions was associated with mRS ≥3 at 90 days. The definition of >15% CBV or CBF asymmetry was the only definition that improved model fit on BIC analysis (ΔBIC = -8.105) and demonstrated an association between no-reflow and clinical outcome among patients with eTICI3 reperfusion. CONCLUSIONS: Existing imaging definitions of no-reflow varied significantly in prevalence and post-treatment perfusion imaging profile, potentially explaining the variable prevalence of no-reflow reported in literature. The definition of >15% CBV or CBF asymmetry best discriminated for functional outcome at 90 days, including patients with eTICI3 reperfusion. ANN NEUROL 2024;96:1104-1114.
引用
- Mutimer CA, Mujanovic A, Kaesmacher J, et al. Comparison of Perfusion Imaging Definitions of the No-Reflow Phenomenon after Thrombectomy-What Is the Best Perfusion Imaging Definition? Ann Neurol. 2024. PMID: 39225109. doi:10.1002/ana.27073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。